Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV.

Ehrhardt SA, Zehner M, Krähling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu MS, Schommers P, Gieselmann L, Eggeling R, Dahlke C, Wolf T, Pfeifer N, Addo MM, Diskin R, Becker S, Klein F.

Nat Med. 2019 Oct;25(10):1589-1600. doi: 10.1038/s41591-019-0602-4. Epub 2019 Oct 7.

PMID:
31591605
2.

Optimizing antibody affinity and stability by the automated design of the variable light-heavy chain interfaces.

Warszawski S, Borenstein Katz A, Lipsh R, Khmelnitsky L, Ben Nissan G, Javitt G, Dym O, Unger T, Knop O, Albeck S, Diskin R, Fass D, Sharon M, Fleishman SJ.

PLoS Comput Biol. 2019 Aug 23;15(8):e1007207. doi: 10.1371/journal.pcbi.1007207. eCollection 2019 Aug.

3.

Intestinal Gel-Forming Mucins Polymerize by Disulfide-Mediated Dimerization of D3 Domains.

Javitt G, Calvo MLG, Albert L, Reznik N, Ilani T, Diskin R, Fass D.

J Mol Biol. 2019 Sep 6;431(19):3740-3752. doi: 10.1016/j.jmb.2019.07.018. Epub 2019 Jul 13.

4.

Variations in Core Packing of GP2 from Old World Mammarenaviruses in their Post-Fusion Conformations Affect Membrane-Fusion Efficiencies.

Shulman A, Katz M, Cohen-Dvashi H, Greenblatt HM, Levy Y, Diskin R.

J Mol Biol. 2019 May 17;431(11):2095-2111. doi: 10.1016/j.jmb.2019.04.012. Epub 2019 Apr 18.

PMID:
31004664
5.

Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junín Viruses.

Borenstein-Katz A, Shulman A, Hamawi H, Leitner O, Diskin R.

J Virol. 2019 Apr 3;93(8). pii: e00090-19. doi: 10.1128/JVI.00090-19. Print 2019 Apr 15.

6.

Rapid characterization of secreted recombinant proteins by native mass spectrometry.

Ben-Nissan G, Vimer S, Warszawski S, Katz A, Yona M, Unger T, Peleg Y, Morgenstern D, Cohen-Dvashi H, Diskin R, Fleishman SJ, Sharon M.

Commun Biol. 2018 Dec 3;1:213. doi: 10.1038/s42003-018-0231-3. eCollection 2018.

7.

Structure of Type-I Mycobacterium tuberculosis fatty acid synthase at 3.3 Å resolution.

Elad N, Baron S, Peleg Y, Albeck S, Grunwald J, Raviv G, Shakked Z, Zimhony O, Diskin R.

Nat Commun. 2018 Sep 24;9(1):3886. doi: 10.1038/s41467-018-06440-6.

8.

Expression of a recombinant, 4'-Phosphopantetheinylated, active M. tuberculosis fatty acid synthase I in E. coli.

Baron S, Peleg Y, Grunwald J, Morgenstern D, Elad N, Peretz M, Albeck S, Levin Y, Welch JT, DeWeerd KA, Schwarz A, Burstein Y, Diskin R, Shakked Z, Zimhony O.

PLoS One. 2018 Sep 24;13(9):e0204457. doi: 10.1371/journal.pone.0204457. eCollection 2018.

9.

Structural basis for receptor recognition by Lujo virus.

Cohen-Dvashi H, Kilimnik I, Diskin R.

Nat Microbiol. 2018 Oct;3(10):1153-1160. doi: 10.1038/s41564-018-0224-5. Epub 2018 Aug 27.

PMID:
30150732
10.

Target highlights from the first post-PSI CASP experiment (CASP12, May-August 2016).

Kryshtafovych A, Albrecht R, Baslé A, Bule P, Caputo AT, Carvalho AL, Chao KL, Diskin R, Fidelis K, Fontes CMGA, Fredslund F, Gilbert HJ, Goulding CW, Hartmann MD, Hayes CS, Herzberg O, Hill JC, Joachimiak A, Kohring GW, Koning RI, Lo Leggio L, Mangiagalli M, Michalska K, Moult J, Najmudin S, Nardini M, Nardone V, Ndeh D, Nguyen TH, Pintacuda G, Postel S, van Raaij MJ, Roversi P, Shimon A, Singh AK, Sundberg EJ, Tars K, Zitzmann N, Schwede T.

Proteins. 2018 Mar;86 Suppl 1:27-50. doi: 10.1002/prot.25392. Epub 2017 Oct 16.

11.

Structural Basis for Receptor Selectivity by the Whitewater Arroyo Mammarenavirus.

Shimon A, Shani O, Diskin R.

J Mol Biol. 2017 Sep 1;429(18):2825-2839. doi: 10.1016/j.jmb.2017.07.011. Epub 2017 Jul 21.

PMID:
28736175
12.

Mapping of the Lassa virus LAMP1 binding site reveals unique determinants not shared by other old world arenaviruses.

Israeli H, Cohen-Dvashi H, Shulman A, Shimon A, Diskin R.

PLoS Pathog. 2017 Apr 27;13(4):e1006337. doi: 10.1371/journal.ppat.1006337. eCollection 2017 Apr.

13.

Role of LAMP1 Binding and pH Sensing by the Spike Complex of Lassa Virus.

Cohen-Dvashi H, Israeli H, Shani O, Katz A, Diskin R.

J Virol. 2016 Oct 28;90(22):10329-10338. doi: 10.1128/JVI.01624-16. Print 2016 Nov 15.

14.

Molecular Mechanism for LAMP1 Recognition by Lassa Virus.

Cohen-Dvashi H, Cohen N, Israeli H, Diskin R.

J Virol. 2015 Aug;89(15):7584-92. doi: 10.1128/JVI.00651-15. Epub 2015 May 13.

15.

HIV. Expanding the breadth of an HIV-1 vaccine.

Ofek G, Diskin R.

Science. 2014 Dec 12;346(6215):1290-1. doi: 10.1126/science.aaa2315. No abstract available.

PMID:
25504701
16.

Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques.

Shingai M, Donau OK, Plishka RJ, Buckler-White A, Mascola JR, Nabel GJ, Nason MC, Montefiori D, Moldt B, Poignard P, Diskin R, Bjorkman PJ, Eckhaus MA, Klein F, Mouquet H, Cetrulo Lorenzi JC, Gazumyan A, Burton DR, Nussenzweig MC, Martin MA, Nishimura Y.

J Exp Med. 2014 Sep 22;211(10):2061-74. doi: 10.1084/jem.20132494. Epub 2014 Aug 25.

17.

Restricting HIV-1 pathways for escape using rationally designed anti-HIV-1 antibodies.

Diskin R, Klein F, Horwitz JA, Halper-Stromberg A, Sather DN, Marcovecchio PM, Lee T, West AP Jr, Gao H, Seaman MS, Stamatatos L, Nussenzweig MC, Bjorkman PJ.

J Exp Med. 2013 Jun 3;210(6):1235-49. doi: 10.1084/jem.20130221. Epub 2013 May 27.

18.

Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization.

Klein F, Diskin R, Scheid JF, Gaebler C, Mouquet H, Georgiev IS, Pancera M, Zhou T, Incesu RB, Fu BZ, Gnanapragasam PN, Oliveira TY, Seaman MS, Kwong PD, Bjorkman PJ, Nussenzweig MC.

Cell. 2013 Mar 28;153(1):126-38. doi: 10.1016/j.cell.2013.03.018.

19.

Structural basis for HIV-1 gp120 recognition by a germ-line version of a broadly neutralizing antibody.

Scharf L, West AP Jr, Gao H, Lee T, Scheid JF, Nussenzweig MC, Bjorkman PJ, Diskin R.

Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6049-54. doi: 10.1073/pnas.1303682110. Epub 2013 Mar 22.

20.

Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs.

Hoot S, McGuire AT, Cohen KW, Strong RK, Hangartner L, Klein F, Diskin R, Scheid JF, Sather DN, Burton DR, Stamatatos L.

PLoS Pathog. 2013 Jan;9(1):e1003106. doi: 10.1371/journal.ppat.1003106. Epub 2013 Jan 3. Erratum in: PLoS Pathog. 2013 Jul;9(9). doi:10.1371/annotation/ed7c0148-97eb-4416-824d-6e6d1aaeceef.

21.

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

Klein F, Halper-Stromberg A, Horwitz JA, Gruell H, Scheid JF, Bournazos S, Mouquet H, Spatz LA, Diskin R, Abadir A, Zang T, Dorner M, Billerbeck E, Labitt RN, Gaebler C, Marcovecchio P, Incesu RB, Eisenreich TR, Bieniasz PD, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC.

Nature. 2012 Dec 6;492(7427):118-22. doi: 10.1038/nature11604. Epub 2012 Oct 24.

22.

A mouse model for HIV-1 entry.

Pietzsch J, Gruell H, Bournazos S, Donovan BM, Klein F, Diskin R, Seaman MS, Bjorkman PJ, Ravetch JV, Ploss A, Nussenzweig MC.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15859-64. Epub 2012 Sep 10.

23.

Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120.

West AP Jr, Diskin R, Nussenzweig MC, Bjorkman PJ.

Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):E2083-90. doi: 10.1073/pnas.1208984109. Epub 2012 Jun 27.

24.

Increasing the potency and breadth of an HIV antibody by using structure-based rational design.

Diskin R, Scheid JF, Marcovecchio PM, West AP Jr, Klein F, Gao H, Gnanapragasam PN, Abadir A, Seaman MS, Nussenzweig MC, Bjorkman PJ.

Science. 2011 Dec 2;334(6060):1289-93. doi: 10.1126/science.1213782. Epub 2011 Oct 27.

25.

Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding.

Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch J, Fenyo D, Abadir A, Velinzon K, Hurley A, Myung S, Boulad F, Poignard P, Burton DR, Pereyra F, Ho DD, Walker BD, Seaman MS, Bjorkman PJ, Chait BT, Nussenzweig MC.

Science. 2011 Sep 16;333(6049):1633-7. doi: 10.1126/science.1207227. Epub 2011 Jul 14.

26.

Active mutants of the TCR-mediated p38α alternative activation site show changes in the phosphorylation lip and DEF site formation.

Tzarum N, Diskin R, Engelberg D, Livnah O.

J Mol Biol. 2011 Feb 4;405(5):1154-69. doi: 10.1016/j.jmb.2010.11.023. Epub 2010 Dec 10.

PMID:
21146537
27.

Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity.

Diskin R, Marcovecchio PM, Bjorkman PJ.

Nat Struct Mol Biol. 2010 May;17(5):608-13. doi: 10.1038/nsmb.1796. Epub 2010 Mar 31.

28.

The crystal structure of CHIR-AB1: a primordial avian classical Fc receptor.

Arnon TI, Kaiser JT, West AP Jr, Olson R, Diskin R, Viertlboeck BC, Göbel TW, Bjorkman PJ.

J Mol Biol. 2008 Sep 12;381(4):1012-24. doi: 10.1016/j.jmb.2008.06.082. Epub 2008 Jul 3.

29.

A novel lipid binding site formed by the MAP kinase insert in p38 alpha.

Diskin R, Engelberg D, Livnah O.

J Mol Biol. 2008 Jan 4;375(1):70-9. Epub 2007 Sep 8.

PMID:
17999933
30.

High-resolution diffracting crystals of intrinsically active p38alpha MAP kinase: a case study for low-throughput approaches.

Diskin R, Engelberg D, Livnah O.

Acta Crystallogr D Biol Crystallogr. 2007 Feb;63(Pt 2):260-5. Epub 2007 Jan 16.

PMID:
17242519
31.

Intrinsically active variants of all human p38 isoforms.

Avitzour M, Diskin R, Raboy B, Askari N, Engelberg D, Livnah O.

FEBS J. 2007 Feb;274(4):963-75. Epub 2007 Jan 22.

32.

Hyperactive variants of p38alpha induce, whereas hyperactive variants of p38gamma suppress, activating protein 1-mediated transcription.

Askari N, Diskin R, Avitzour M, Capone R, Livnah O, Engelberg D.

J Biol Chem. 2007 Jan 5;282(1):91-9. Epub 2006 Nov 6.

33.

Structures of p38alpha active mutants reveal conformational changes in L16 loop that induce autophosphorylation and activation.

Diskin R, Lebendiker M, Engelberg D, Livnah O.

J Mol Biol. 2007 Jan 5;365(1):66-76. Epub 2006 Aug 22.

PMID:
17059827
34.

JX401, A p38alpha inhibitor containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast.

Friedmann Y, Shriki A, Bennett ER, Golos S, Diskin R, Marbach I, Bengal E, Engelberg D.

Mol Pharmacol. 2006 Oct;70(4):1395-405. Epub 2006 Jul 17.

PMID:
16847144
35.

MAP-quest: could we produce constitutively active variants of MAP kinases?

Askari N, Diskin R, Avitzour M, Yaakov G, Livnah O, Engelberg D.

Mol Cell Endocrinol. 2006 Jun 27;252(1-2):231-40. Epub 2006 May 2. Review.

PMID:
16672172
36.

Active mutants of the human p38alpha mitogen-activated protein kinase.

Diskin R, Askari N, Capone R, Engelberg D, Livnah O.

J Biol Chem. 2004 Nov 5;279(45):47040-9. Epub 2004 Jul 28.

Supplemental Content

Loading ...
Support Center